One Reason Why Shire (SHPG) Stock is Advancing Today

NEW YORK (TheStreet) -- Shares of Shire PLC (SHPG - Get Report) are higher by 6.76% to $185.11 in early afternoon trading on Wednesday, as the company announced earlier this week that its ADHD drug met its primary endpoints in a phase III trial.

The company announced positive top-line results from the phase III trial, SHP465-305, for its pipeline candidate SHP465.

The trail lasted four weeks and was a double blind, multi-center, randomized, placebo controlled study that evaluated the safety and efficacy of SHP465 in children and teens between the ages of six and 17 that suffer from attention deficit/hyperactivity disorder.

Back by Popular Demand…“Confessions of a Street Addict” Get a FREE signed copy of Jim Cramer’s national best-seller when you gain access to his...